Frederick National Laboratory for Cancer Research. Bioinformatics, Big Data, and Cancer. Annual Report to the Nation. Research Advances by Cancer Type. Stories of Discovery. Milestones in Cancer Research and Discovery. Biomedical Citizen Science. Director's Message. Budget Proposal. Stories of Cancer Research. Driving Discovery.
Highlighted Scientific Opportunities. Research Grants. Research Funding Opportunities. Cancer Grand Challenges. Research Program Contacts. Funding Strategy. Grants Policies and Process. Introduction to Grants Process. NCI Grant Policies. Legal Requirements. Step 3: Peer Review and Funding Outcomes. Manage Your Award. Grants Management Contacts. Prior Approvals. Annual Reporting and Auditing. Transfer of a Grant. Grant Closeout. Cancer Training at NCI. Resources for Trainees.
Funding for Cancer Training. Building a Diverse Workforce. National Cancer Act 50th Anniversary Commemoration. Resources for News Media. Media Contacts. Cancer Reporting Fellowships. Advisory Board Meetings. Social Media Events. Indianapolis, Indiana, United States, Van Elslander Cancer Center at St.
John Hospital and Medical Center. Hubert H. Robbinsdale, Minnesota, United States, Francis Medical Center. Kansas City Cancer Center at St. Joseph's Medical Mall. Montana Cancer Center at St. Patrick Hospital and Health Sciences Center. Frederick R. Smith Cancer Treatment Center. Charlotte, North Carolina, United States, Greenville, North Carolina, United States, Hendersonville, North Carolina, United States, Rutherfordton, North Carolina, United States, David L.
Ruth G. Francis Hospital. Danville, Pennsylvania, United States, East Stroudsburg, Pennsylvania, United States, Hershey Medical Center. Hershey, Pennsylvania, United States, Abramson Cancer Center of the University of Pennsylvania.
Philadelphia, Pennsylvania, United States, Reading, Pennsylvania, United States, Hematology and Oncology Associates of Northeastern Pennsylvania. Sellersville, Pennsylvania, United States, State College, Pennsylvania, United States, West Chester, Pennsylvania, United States, Frank M. Wilkes-Barre, Pennsylvania, United States, Williamsport, Pennsylvania, United States, Time to treatment failure, response duration and time to first cytotoxic therapy With a median follow-up of 4.
Figure 2. Figure 3. Table 3 Reasons for treatment failure after randomization to retreatment rituximab RR or maintenance rituximab MR. Figure 4. Disease transformation and overall survival Of the non-follicular patients, four randomized to RR developed transformed lymphoma.
Figure 5. Toxicity Grade 3 toxicities were infrequent and included allergic reaction or rash 3 events , ventricular arrhythmia, fatigue, infection, syncope, neuropathic pain and dyspnea 1 event each , and cytokine release syndrome 2 events Table 4. Resource utilization Accounting for all administered rituximab doses for the 52 patients randomized to step 2, including the 4 induction doses, patients assigned to RR received an average of 5. Discussion Achieving and maintaining durable remission in patients with advanced-stage SLL and MZL remains an unmet challenge in lymphoma patient care.
Footnotes Presented in part at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA Authorship Michael Williams: protocol development, patient enrollment, data analysis, manuscript writing Fangxin Hong: data analysis, manuscript writing Randy Gascoyne: pathology review, manuscript editing Lynne Wagner: protocol development, manuscript editing John Krauss: protocol development, patient enrollment Sandra Horning: protocol development, patient enrollment Thomas Habermann: patient enrollment, manuscript editing Lode Swinnen: patient enrollment, manuscript editing Stephen Schuster: patient enrollment, manuscript editing Christopher Peterson: patient enrollment, manuscript editing Mark Sborov: patient enrollment, manuscript editing S.
Eric Martin: patient enrollment, manuscript editing Matthias Weiss: patient enrollment, manuscript editing W. Christopher Ehmann: patient enrollment, manuscript editing Brad Kahl: protocol development, patient enrollment, data analysis, manuscript writing Author disclosures Michael E. Fangxin Hong: None Randy D. Wagner: None John C. Krauss: None Thomas M. Habermann: None Lode J. Swinnnen: None Stephen J. Schuster: None Christopher G. Peterson: None Mark D. Sborov: None S. Christopher Ehmann: None Sandra J.
Association of serum rituximab IDEC-C2B8 concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Journal of Clinical Oncology. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
New England Journal of Medicine. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncology.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. New England Journal of Med Phase II trial of indivisualized rituximab dosing for patients with CDpositive lymphoproliferative disorders. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.
The Oncologist. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphoma treated with a rituximab-intensive program. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. Support Center Support Center. External link. Please review our privacy policy.
MZL, splenic. MZL, nodal. At progression, patients in the retreatment group restarted the treatment strategy with four doses of rituximab.
Kahl reported updated findings after a median follow-up of The objectives of the update were to examine the time to first cytotoxic therapy, duration of response DOR , OS, and risk of leukemic transformation.
The difference represented a hazard ratio of 2. The median DOR to induction rituximab was 3. The key outcomes of OS, transformation risk, and second malignancy did not differ between treatment strategies.
0コメント